Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | DS-7300 demonstrates durable antitumor activity in advanced solid tumors

Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Chiba, Japan, shares the results of an extended follow-up of a Phase I/II (NCT04145622) investigating DS-7300, a B7-H3–directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload (DXd), in various cancers including small cell lung cancer (SCLC), metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC). DS-7300 continues to demonstrate evidence of durable antitumor activity in heavily pre-treated patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.